Famous Patents
In 1879, Auguste Bartholdi received design patent number 11,023 titled "Design for a Statue". It was for the Statue of Liberty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178571 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alphaadrenergic agonists and methods for using the same Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical composition... | 05/15/2012 |
| 8071635 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazole-2-ones and related compounds Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in ... | 12/06/2011 |
| 8063231 | Methods of treating alpha adrenergic mediated conditions Described herein are novel N-(2 and/or 3-substituted benzyl)-4,5-dihydro-1H-imidazol-2-amine derivatives processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals modulators of subtype α2B and/or α2C... | 11/22/2011 |
| 8063087 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in ... | 11/22/2011 |
| 8063086 | Imidazole-2-thiones Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha | 11/22/2011 |
| 8063033 | Therapeutic beta-lactams Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y is A is —(CH2)6—, cis —CH2CH═CH... | 11/22/2011 |
| 8062657 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not si... | 11/22/2011 |
| 8049037 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof This invention provides compounds as shown below, in which either all of Z1-6 are carbon or one of Z1-6 is nitrogen and the rest are carbon, and in which other substituents are defined herein, which are sphingosine-1-phosphate antagonists. ... | 11/01/2011 |
| 8044092 | Therapeutic compounds A compound having a substituted five or six-membered carbocycle or heterocycle directly bonded to a substituted aryl or heteroaryl ring, wherein said compound has an EC50 value of 20 nM or less at the prostaglandin EP2 receptor according to the... | 10/25/2011 |
| 8039507 | Therapeutic substituted gamma lactams Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments... | 10/18/2011 |
| 8034957 | Kinase inhibitors The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ... | 10/11/2011 |
| 8013000 | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals. ... | 09/06/2011 |
| 8008338 | Ketorolac tromethamine compositions for treating or preventing ocular pain Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein. ... | 08/30/2011 |
| 7993634 | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be a... | 08/09/2011 |
| 7979996 | Breast implant selector systems A breast implant selector system including a breast width selector for selecting breast width input information, a breast tissue type selector for selecting breast tissue type input information in response to breast width input information selected with the breast w... | 07/19/2011 |
| 7977351 | Heteroaryl dihydroindolones as kinase inhibitors The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method f... | 07/12/2011 |
| 7977335 | Methods of preventing and reducing the severity of stress-associated conditions The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereois... | 07/12/2011 |
| 7968711 | Abnormal cannabidiols as agents for lowering intraocular pressure The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I | 06/28/2011 |
| 7964191 | Compositions and methods for the treatment of ophthalmic disease Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions. ... | 06/21/2011 |
| D637287 | Combination handheld delivery device and controller unit | 05/03/2011 |
| 7931909 | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye t... | 04/26/2011 |
| 7902251 | Method for treating pain The present invention provides pharmaceutical compositions useful in a method for treating neuropathic pain, said method comprising administration of a pain-ameliorating effective amount of the compound according to formula I | 03/08/2011 |
| 7884115 | Methods and compositions for the treatment of pain and other neurological conditions Methods and compositions for the treatment of conditions including stress-associated, chronic pain, and neurodegenerative conditions in a mammal using a composition comprising NB-DNJ or a compound structurally similar thereto. ... | 02/08/2011 |
| 7833966 | Enhanced ocular neuroprotection and neurostimulation Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed. ... | 11/16/2010 |
| 7815917 | Botulinum neurotoxin serotype B activatable Botulinum neurotoxin serotype Bs The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleava... | 10/19/2010 |
| 7811299 | Closure system for tubular organs In one embodiment, a surgically implantable adjustable ring comprises a ring body, which includes a closure system having first and second end parts. The ring body is designed to be closed around a tubular organ by the closure system, constricting the tubular organ ... | 10/12/2010 |
| 7811298 | Fatigue-resistant gastric banding device A fatigue-resistant inflatable gastric banding device suitable for laparoscopic placement around the stomach of a patient for the treatment of obesity and a method for such treatment are disclosed. The device includes a gastric band having a chambered inflatable mem... | 10/12/2010 |
| 7811275 | Methods of implanting an injection port A surgical fastening system for implantable devices is disclosed. The implantable device may contain a plurality of fasteners in pre-deployment position, may have a housing fitted over or around it which contains a plurality of fasteners in pre-deployment position, ... | 10/12/2010 |
| 7798954 | Hydraulic gastric band with collapsible reservoir A self-regulating gastric band apparatus for adjusting stoma size. The apparatus includes an adjustable gastric band that has an inner ring expanding with injected fluid. A band adjustment assembly is provided for implanting with the gastric band that includes a sen... | 09/21/2010 |
| 7795292 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical composition... | 09/14/2010 |
| 7786154 | Substituted gamma lactams as therapeutic agents A compound having the formula or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds ar... | 08/31/2010 |
| 7786150 | Therapeutic compounds Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed. ... | 08/31/2010 |
| 7786117 | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J, B, Y, G and A are as described. Methods, compositions, and medicaments related thereto are also di... | 08/31/2010 |
| 7781482 | Substituted gamma lactams as therapeutic agents A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds a... | 08/24/2010 |
| 7780968 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 08/24/2010 |
| 7780590 | Method for locating an implanted fluid access port An implanted fluid access port locator system for adjustable gastric bands. The system may include an access port having an RFID tag with its antenna adjacent to the receiving portion of the port. An external locator with radio frequency transmitter/receiver circuit... | 08/24/2010 |
| 7772392 | Therapeutic substituted β-lactams Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein a dashed line indicates the presence or absence of a bond; Y is an organic ... | 08/10/2010 |
| 7767718 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 08/03/2010 |
| 7763651 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 07/27/2010 |
| 7762998 | Implantable device fastening system and methods of use A surgical fastening system for implantable devices is disclosed. The implantable device may contain a plurality of fasteners in pre-deployment position, may have a housing fitted over or around it which contains a plurality of fasteners in pre-deployment position, ... | 07/27/2010 |
